Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Earlier, the court had declined Novo’s plea for an interim injunction against Dr Reddy’s Labs and permitted the company to ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...